VALN News and Press, Valneva SE From 03/29/23

2023-03-29 22:56:19 ET Summary Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial. The CHIKV vaccine candidate is on track for PDUFA in August 2023, and the company plans to launch one or two programs i...

2023-03-24 13:36:06 ET Valneva ( NASDAQ: VALN ) and Pfizer ( NYSE: PFE ) have pushed back by a year the end date of a phase 3 trial for their Lyme disease vaccine candidate VLA15. The new estimated completion date for the VALOR trial is December 2025, according to ...

2023-03-23 13:25:03 ET Valneva SE (VALN) Q4 2022 Earnings Conference Call March 23, 2023 10:00 a.m. ET Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - Chief Executive Officer Peter Buhler - Chief Financial Officer ...

2023-03-23 09:55:26 ET The following slide deck was published by Valneva SE in conjunction with their 2022 Q4 earnings call. For further details see: Valneva SE 2022 Q4 - Results - Earnings Call Presentation

2023-03-23 02:06:00 ET Valneva press release ( NASDAQ: VALN ): FY GAAP EPS of €1.24. Revenue of €361.3M (+3.8% Y/Y). Adjusted EBITDA loss in 2022 was €69.2 million compared to an adjusted EBITDA loss of €47.1 million in 2...

Valneva ( NASDAQ: VALN ) said the shelf life of its COVID-19 vaccine VLA2001 was extended by regulators to 21 months from 18 months previously, while providing clinical and regulatory updates for the vaccine. The French company had previously noted that it will not...

Summary Valneva SE is a French biotechnology company specializing in developing and commercializing vaccines. We expect approval of two attractive vaccine candidates targeting Chikungunya and Lyme disease by 2024-2025. The company has a relatively cheap valuation, enterprise value o...

The U.S. Food and Drug Administration (FDA) granted priority review to Valneva ( NASDAQ: VALN ) application seeking approval of single-shot chikungunya vaccine candidate VLA1553. The FDA accepted the company's biologics license application (BLA) and is expected to make a decision ...

Valneva press release ( NASDAQ: VALN ): FY cash and cash equivalents were €289.4 million as of December 31, 2022, compared to €346.7 million as of December 31, 2021. Revenue of €361.3M (+3.8% Y/Y). Full year 2023 sales guidance : €13...

Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) said it completed enrollment and vaccination for a phase 3 trial of its single-shot chikungunya vaccine VLA1553 in adolescents. First results of the trial, dubbed  VLA1553-321, are expected mid-2023. The trial was conduct...